CIK 0002023658 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Bicara Therapeutics Inc.
Sign in to watch- Ticker
- BCAX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-468-4219
- Business address
- 116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $400,716
- in 1 filing, $401K under 10b5-1 plans
Net −$400,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-26 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase · Pre-Funded Warrant (Right to Buy) | +2,200,000 | $16.00 | $35.2M | 2,200,000 |
| 2026-02-25 | Cohlhepp Ryan President and COO | Option exercise 10b5-1 | +3,108 | $3.79 | $12K | 213,272 |
| 2026-02-25 | Cohlhepp Ryan President and COO | Sale 10b5-1 | −3,108 | $18.04 | $56K | 210,164 |
| 2026-02-25 | Cohlhepp Ryan President and COO | Sale 10b5-1 | −523 | $18.04 | $9K | 209,641 |
| 2026-02-25 | Cohlhepp Ryan President and COO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,108 | 138,226 | ||
| 2026-02-02 | Cohlhepp Ryan President and COO | Grant or award · Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2026-02-02 | Mazumdar Claire Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +450,000 | 450,000 | ||
| 2026-02-02 | Raben David Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2026-02-02 | Hyep Ivan Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2026-02-02 | Meisner Lara Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +90,000 | 90,000 | ||
| 2026-01-22 | Cohlhepp Ryan President and COO | Sale 10b5-1 | −3,828 | $18.10 | $69K | 210,164 |
| 2026-01-22 | Hyep Ivan Chief Financial Officer | Option exercise 10b5-1 | +1,882 | $3.79 | $7K | 147,237 |
| 2026-01-22 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −1,882 | $18.15 | $34K | 145,355 |
| 2026-01-22 | Hyep Ivan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,882 | 65,462 | ||
| 2026-01-15 | Cohlhepp Ryan President and COO | Sale 10b5-1 | −149 | $18.02 | $3K | 213,992 |
| 2025-12-26 | Cohlhepp Ryan President and COO | Option exercise | +25,000 | $4.44 | $111K | 214,141 |
| 2025-12-26 | Cohlhepp Ryan President and COO | Option exercise · Stock Option (Right to Buy) | −25,000 | 39,909 | ||
| 2025-12-26 | Raben David Chief Medical Officer | Option exercise | +19,789 | $3.79 | $75K | 55,286 |
| 2025-12-26 | Raben David Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −19,789 | 98,987 | ||
| 2025-12-22 | Hyep Ivan Chief Financial Officer | Option exercise 10b5-1 | +9,200 | $3.79 | $35K | 154,555 |
Page 7 of 14 · 276 trades